

## Special Issue

# RNA-Based Vaccines Development

### Message from the Guest Editor

RNA therapeutics comprise a rapidly expanding category of prophylactic and therapeutic vaccines that will speed up the progression of therapeutics to the clinic. RNA-based vaccines also have the potential to actualize personalized medicine and the ability to make the term “undruggable” obsolete. The recent developments in the upstream generation, downstream purification, and cellular delivery of RNA have enabled the development of RNA-based therapeutics for a variety of vaccines. The main focus of this Special Issue is to critically analyze the current strategies in the field of RNA-based vaccines against both cancer and infectious disease. We are aiming to shed light on new emerging technologies as well as to illustrate the effect of vaccines. Classes of RNA-based therapeutics include aptamers, antisense oligonucleotides, microRNAs, small interfering RNAs, and messenger RNA. Additionally, articles describing the developments of nanocarriers for RNA-based vaccines are also invited. We also invite papers that describe the advantages and disadvantages of the clinical translation of prophylactic and therapeutic vaccines.

---

### Guest Editor

Dr. Vrinda Gote  
Viral Vaccines R&D, Inventprise Inc., Redmond, WA, USA

---

### Deadline for manuscript submissions

closed (25 August 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/160243](https://mdpi.com/si/160243)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).